SILVESTRI, ELENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.388
EU - Europa 7.798
AS - Asia 4.603
SA - Sud America 758
Continente sconosciuto - Info sul continente non disponibili 258
AF - Africa 152
OC - Oceania 53
Totale 25.010
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.154
RU - Federazione Russa 2.549
IT - Italia 1.647
PL - Polonia 1.312
SG - Singapore 1.245
CN - Cina 1.120
HK - Hong Kong 698
BR - Brasile 584
IE - Irlanda 580
VN - Vietnam 525
SE - Svezia 408
KR - Corea 349
FR - Francia 288
FI - Finlandia 249
DE - Germania 231
GB - Regno Unito 186
IN - India 159
CA - Canada 148
JO - Giordania 98
BD - Bangladesh 93
CH - Svizzera 83
ID - Indonesia 57
AR - Argentina 56
JP - Giappone 53
AU - Australia 51
ES - Italia 51
AT - Austria 45
EC - Ecuador 41
TR - Turchia 41
CI - Costa d'Avorio 38
MX - Messico 37
NL - Olanda 36
UA - Ucraina 35
ZA - Sudafrica 35
MA - Marocco 32
IQ - Iraq 30
BE - Belgio 24
CO - Colombia 20
PK - Pakistan 19
VE - Venezuela 18
SA - Arabia Saudita 14
IR - Iran 12
PY - Paraguay 12
CL - Cile 10
UZ - Uzbekistan 10
CR - Costa Rica 9
CZ - Repubblica Ceca 9
JM - Giamaica 8
LT - Lituania 8
PH - Filippine 8
AL - Albania 7
KZ - Kazakistan 7
NG - Nigeria 7
PE - Perù 7
TN - Tunisia 7
AE - Emirati Arabi Uniti 6
DZ - Algeria 6
KE - Kenya 6
NP - Nepal 6
RO - Romania 6
UY - Uruguay 6
AM - Armenia 5
BJ - Benin 5
EG - Egitto 5
GT - Guatemala 5
HN - Honduras 5
BG - Bulgaria 4
DK - Danimarca 4
EE - Estonia 4
HR - Croazia 4
HU - Ungheria 4
IL - Israele 4
MM - Myanmar 4
PS - Palestinian Territory 4
TT - Trinidad e Tobago 4
TW - Taiwan 4
BB - Barbados 3
DO - Repubblica Dominicana 3
GR - Grecia 3
KG - Kirghizistan 3
KH - Cambogia 3
LA - Repubblica Popolare Democratica del Laos 3
LB - Libano 3
MD - Moldavia 3
MU - Mauritius 3
PA - Panama 3
PT - Portogallo 3
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
BY - Bielorussia 2
EU - Europa 2
GE - Georgia 2
LK - Sri Lanka 2
LV - Lettonia 2
MC - Monaco 2
MY - Malesia 2
NZ - Nuova Zelanda 2
OM - Oman 2
QA - Qatar 2
Totale 24.720
Salva come PNG Salva come JPEG
Città #
Santa Clara 2.131
Ashburn 1.514
Warsaw 1.306
Fairfield 861
Singapore 858
Hong Kong 589
Dublin 577
Chandler 459
San Jose 458
Woodbridge 377
Seoul 347
Houston 338
Seattle 334
Cambridge 310
Milan 293
Beijing 282
Wilmington 233
Florence 230
Lawrence 178
Los Angeles 178
New York 177
Council Bluffs 175
Buffalo 165
Hefei 164
Ho Chi Minh City 158
Altamura 156
Helsinki 140
Princeton 136
Munich 129
Ann Arbor 126
Paris 121
Boston 115
Rome 113
Dallas 112
Lauterbourg 110
Moscow 110
Hanoi 109
The Dalles 103
Mumbai 83
Bern 77
Turku 65
Chicago 64
Phoenix 63
Shanghai 63
Clifton 60
San Diego 60
Boardman 59
São Paulo 54
Melbourne 48
Kent 47
Medford 46
Tokyo 43
Vienna 42
Jakarta 41
London 40
Abidjan 38
Dong Ket 36
Orem 36
Guangzhou 34
Toronto 34
Bologna 31
Frankfurt am Main 31
Montreal 31
Da Nang 30
Naples 30
Turin 30
Falls Church 29
Norwalk 29
Chennai 28
Redondo Beach 28
Barcelona 27
Brooklyn 26
Johannesburg 26
Rio de Janeiro 26
Casablanca 23
Denver 23
Atlanta 21
Brussels 21
Stockholm 21
Palermo 20
Figino 19
Hillsboro 19
Tianjin 19
Jacksonville 18
Manchester 18
Biên Hòa 17
Haiphong 17
Genoa 16
Washington 16
Amsterdam 15
Quito 15
Baghdad 14
Redwood City 14
Bari 13
Barnet 13
City of London 13
Miano 13
Shenzhen 13
Venice 13
Belo Horizonte 12
Totale 16.243
Salva come PNG Salva come JPEG
Nome #
Behçet's syndrome patients exhibit specific microbiome signature. 524
An approach to differential diagnosis of antiphospholipid antibody syndrome and related conditions. 364
Long-term efficacy and safety of anakinra in a patient with Behçet's disease and concomitant tuberculosis infection 342
Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside 319
Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet’s syndrome 313
SIRT1 activity is decreased in lesional psoriatic skin 302
Neutrophil Activation Promotes Fibrinogen Oxidation and Thrombus Formation in Behçet’s Disease 289
T cells in gastric cancer: friends or foes. 280
A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. 277
Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie Società Italiana di Medicina Interna) Study 277
Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study 267
Repeated low-dose courses of rituximab in SLE-associated antiphospholipid syndrome: Data from a tertiary dedicated centre 264
Digital ulcers secondary to Sneddon's syndrome successfully treated with Bosentan: not only useful in Systemic Sclerosis 255
Multimorbidity and polypharmacy in the elderly: Lessons from REPOSI 255
Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia 243
Brief Report: Rituximab for the treatment of adult-onset IgA vasculitis (Henoch-Schönlein purpura) 239
Polypharmacy in older people: lessons from 10 years of experience with the REPOSI register 238
Intravenous immunoglobulin for the secondary prevention of stillbirth in obstetric antiphospholipid syndrome: A case series and systematic review of literature 234
First report of FIP1L1-PDGFR alpha-positive eosinophilic granulomatosis with polyangiitis 230
Thrombosis in Autoimmune Diseases: A Role for Immunosuppressive Treatments? 230
MRI evaluation of the "central vein sign" in brain white matter lesions of multiple sclerosis and systemic autoimmune diseases. 223
Thrombosis in vasculitis: from pathogenesis to treatment 222
Intravenous immunoglobulin therapy: a snapshot for the internist. 217
Cytotoxic Th1 and Th17 cells infiltrate the intestinal mucosa of Behcet patients and exhibit high levels of TNF-α in early phases of the disease 216
Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes 214
Behçet's syndrome as a tool to dissect the mechanisms of thrombo-inflammation: clinical and pathogenetic aspects 213
Implementation of the Frailty Index in hospitalized older patients: Results from the REPOSI register 213
A new cytofluorimetric approach to evaluate the circulating microparticles in subjects with antiphospholipid antibodies 210
Alveolar haemorrhage in ANCA-associated vasculitis: Long-term outcome and mortality predictors 210
Defining aging phenotypes and related outcomes: Clues to recognize frailty in hospitalized older patients 210
Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study 208
Stem-Cell-Derived Circulating Progenitors Dysfunction in Behçet's Syndrome Patients Correlates With Oxidative Stress 207
Prevalence and clinical associations of ultrasound-confirmed enthesitis in systemic lupus erythematosus 206
Pharmacological prevention of venous thromboembolism in orthopaedic surgery 206
Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behçet's phenotype: A multicentre study 206
A unique circulating miRNA profile highlights thrombo-inflammation in Behçet's syndrome 206
Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study 201
Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients 200
Belimumab reduces antiphospholipid antibodies in SLE patients independently of hydroxychloroquine treatment 200
Cardiac involvement in eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome): Prospective evaluation at a tertiary referral centre 199
Thrombosis in inflammatory bowel diseases: What's the link? 197
Systemic lupus erythematosus: immunopathogenesis and novel therapeutic targets 196
Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset still's disease: A multicentre retrospective observational study 196
Mortality rate and risk factors for gastrointestinal bleeding in elderly patients 196
Comparison of treatments for the prevention of fetal growth restriction in obstetric antiphospholipid syndrome: a systematic review and network meta-analysis 196
Adalimumab-Based Treatment Versus Disease-Modifying Antirheumatic Drugs for Venous Thrombosis in Behçet's Syndrome: A Retrospective Study of Seventy Patients With Vascular Involvement 195
Redox status alterations during the competitive season in élite soccer players: focus on peripheral leukocyte-derived ROS 193
Interleukin-17/Interleukin-21 and Interferon-g producing T cells specific for β2 Glycoprotein I in atherosclerosis inflammation of systemic lupus erythematosus patients with antiphospholipid syndrome 193
Non-anti TNFα biologic agents for noninfectious uveitis associated with systemic inflammatory diseases: a systematic review 191
Antihypertensive treatment changes and related clinical outcomes in older hospitalized patients 191
Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly 190
Pathogenesis of Behcet Syndrome 189
Rapid desensitization to anakinra-related delayed reaction: Need for a standardized protocol 188
Long-term retention rate of anakinra in adult onset Still’s disease and predictive factors for treatment response 187
Secukinumab reduces plasma oxidative stress in psoriasis: A case-based experience 185
Impact of cardiovascular and immunologic variables on subclinical carotid atherosclerosis in subjects with anti-phospholipid antibodies 185
β2 Glycoprotein I Recognition Drives Th1 Inflammation in Atherosclerotic Plaques of Patients with Primary Antiphospholipid Syndrome 185
Circulating miRNome profiling data in Behçet's syndrome 183
Susceptibility weighted MRI can help differentiating pathogenesis of white matter lesions in MS and CNS inflammatory vasculopathies. 182
Neutrophil-mediated mechanisms of damage and in vitro protective effect of colchicine in non-vascular Behçet's syndrome 181
Differential Diagnosis 180
Prognostic Value of Degree and Types of Anaemia on Clinical Outcomes for Hospitalised Older Patients 180
CSF/serum matrix metallopeptidase‐9 ratio discriminates neuro Behçet from multiple sclerosis 180
Behçet's syndrome pathophysiology and potential therapeutic targets 179
Anakinra for resistant Behçet uveitis: why not? 177
Need for deprescribing in hospital elderly patients discharged with a limited life expectancy: The REPOSI study 176
What changed in the Italian internal medicine and geriatric wards during the lockdown 176
Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside 174
POS1212 SARS-CoV-2 INFECTION AMONG PATIENTS WITH BEHÇET’S SYNDROME 173
Gut Microbiota and Associated Mucosal Immune Response in Eosinophilic Granulomatosis with Polyangiitis (EGPA) 171
The multifaceted spectrum of liver cirrhosis in older hospitalised patients: analysis of the REPOSI registry 171
Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study 169
Imaging perivenular distribution can differentiate MS from CNS vasculitis. 167
Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study 166
Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome) 166
Reply: anti-IL1 blocking agents in drug-resistant Behçet's syndrome: our little case series 164
Microparticles: Bridging the gap between autoimmunity and thrombosis 163
HELICOBACTER PYLORI HP0175 PROMOTES THE PRODUCTION OF IL-23, IL-6, IL-1 beta AND TGF-beta 162
Serum Interleukin-36 α as a Candidate Biomarker to Distinguish Behçet’s Syndrome and Psoriatic Arthritis 161
Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome 161
The right place of interleukin-1 inhibitors in the treatment of Behçet’s syndrome: a systematic review 161
Mepolizumab versus benralizumab for eosinophilic granulomatosis with polyangiitis (EGPA): A European real-life retrospective comparative study 160
A multicenter approach to evaluate omalizumab effectiveness in Samter's triad 160
Favorable pregnancy outcome in a patient with systemic lupus erythematosus treated with belimumab: A confirmation report 160
Vascular Behçet's syndrome: an update 159
Hospital Care of Older Patients With COPD: Adherence to International Guidelines for Use of Inhaled Bronchodilators and Corticosteroids 159
Efficacy of the anti-IL 17 secukinumab in refractory Behçet's syndrome: A preliminary study 159
Novel oral anticoagulants in Atrial fibrillation: Which novel oral anticoagulant for which patient? 156
Obstetric antiphospholipid syndrome is not associated with an increased risk of subclinical atherosclerosis 155
Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure 155
Behçet's disease as a cause of cerebral sinus vein thrombosis: an emerging role 153
Sharing data of clinical trials 151
Pathogenesis of Behcet Syndrome 150
Drug-specific Treg cells are induced during desensitization procedure for rituximab and tocilizumab in patients with anaphylaxis 149
Rare NLRP12 variants associated with the NLRP12-autoinflammatory disorder phenotype: an Italian case series 149
The association of adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) with cardiovascular disease in subjects with antiphospholipid antibodies 148
Efficacy and safety profile of anti-interleukin-1 treatment in Behçet's disease: a multicenter retrospective study 148
Adalimumab effectiveness in Behçet’s disease: short and long-term data from a multicenter retrospective observational study 148
The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry 147
Epigenetics in autoimmune diseases: Unraveling the hidden regulators of immune dysregulation 146
Totale 20.217
Salva come PNG Salva come JPEG
Categoria #
all - tutte 77.374
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 77.374
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022801 0 0 0 38 29 71 29 100 62 42 167 263
2022/20232.402 206 516 142 108 118 384 339 136 248 31 71 103
2023/20241.126 40 101 160 55 79 223 37 175 36 71 73 76
2024/20256.769 274 680 368 1.187 1.818 784 137 368 299 262 309 283
2025/20267.850 868 948 617 868 844 322 875 333 420 530 242 983
2026/20271.268 228 178 542 320 0 0 0 0 0 0 0 0
Totale 25.010